← Back to Search
Development Of Novel Potent Orally Bioavailable Oseltamivir Derivatives Active Against Resistant Influenza A.
D. Schade, Joscha Kotthaus, Lukas Riebling, J. Kotthaus, H. Müller-Fielitz, W. Raasch, O. Koch, Nora Seidel, M. Schmidtke, B. Clement
Published 2014 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
With the emergence of oseltamivir-resistant influenza viruses and in view of a highly pathogenic flu pandemic, it is important to develop new anti-influenza agents. Here, the development of neuraminidase (NA) inhibitors that were designed to overcome resistance mechanisms along with unfavorable pharmacokinetic (PK) properties is described. Several 5-guanidino- and 5-amidino-based oseltamivir derivatives were synthesized and profiled for their anti-influenza activity and in vitro and in vivo PK properties. Amidine 6 and guanidine 7 were comparably effective against a panel of different A/H1N1 and A/H3N2 strains and also inhibited mutant A/H1N1 neuraminidase. Among different prodrug strategies pursued, a simple amidoxime ethyl ester (9) exhibited a superior PK profile with an oral bioavailability of 31% (rats), which is comparable to oseltamivir (36%). Thus, bioisosteric replacement of the 5-guanidine with an acetamidine-in the form of its N-hydroxy prodrug-successfully tackled the two key limitations of currently used NA inhibitors, as exemplified with oseltamivir.
This paper references
Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide.
B. Clement (1993)
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Katja Bauer (2009)
World Health Organization Influenza Fact Sheet 211; World Health Organization: Geneva
METABOLISM OF N-HYDROXYGUANIDINES (N-HYDROXYDEBRISOQUINE) IN HUMAN AND PORCINE HEPATOCYTES: REDUCTION AND FORMATION OF GLUCURONIDES
A. K. Froehlich (2005)
Stereoselective synthesis of 1,2-diols by the cycloadditive strategy: total synthesis of (±)-exo-brevicomin and (±)-and (–)-pestalotin
J. Zhang (1991)
CS-8958: longacting neuraminidase inhibitors for the treatment of influenza
M Yamashita (2010)
S-2-Naphthylmethyl thioacetimidate hydrobromide: A new odorless reagent for the mild synthesis of substituted acetamidines
B. G. Shearer (1997)
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.
U. Grienke (2010)
Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071
W. Li (1998)
Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
L. Cass (1999)
The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti‐Influenza Drug, Peramivir
V. Arya (2010)
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
H. Nguyen (2012)
Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.
J. Shie (2007)
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
B. Clement (2003)
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Y. Babu (2000)
A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS
L. Reed (1938)
Antivirals targeting influenza A virus.
K. Das (2012)
Development of oseltamivir phosphonate congeners as anti-influenza agents.
T. Cheng (2012)
Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104.
E. Eisenberg (1997)
Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.
Joscha Kotthaus (2011)
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
J. M. Woods (1993)
Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study
Paula E. Miller (2012)
Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz.
B. Clement (1996)
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.
J. Miller (2010)
Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008
Tiffany G. Sheu (2008)
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
Emergence of a novel swine-origin influenza A (H1N1) virus in humans.
Fatimah S. Dawood (2009)
Hydroxylamine base was set free from its hydrochloride salt with sodium ethanolate
R Steudel (1975)
Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors.
C. U. Kim (1998)
In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens.
F. Soriano (1998)
Antiviral agents active against influenza A viruses
E. De Clercq (2006)
UCSF Chimera—A visualization system for exploratory research and analysis
E. F. Pettersen (2004)
S‐2‐Naphthylmethyl Thioacetimidate Hydrobromide: A New Odorless Reagent for the Mild Synthesis of Substituted Acetamidines.
B. G. Shearer (1997)
Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode.
J. Kirchmair (2011)
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations
B. Davies (2010)
Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802
G. He (1999)
Recent Advances in Neuraminidase Inhibitor Development as Anti‐influenza Drugs
E. Feng (2012)
Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration
Shuku Kubo (2010)
Development and validation of a genetic algorithm for flexible docking.
G. Jones (1997)
Are We Ready for Pandemic Influenza?
R. Webby (2003)
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
D. Birnkrant (2009)
A simple method of estimating fifty percent endpoints
L. Reed (1938)
Influenza virus resistance to neuraminidase inhibitors.
D. Mendel (1998)
Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
M. Yamashita (2010)
A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1.
M. Schmidtke (2001)
Human infection with a novel avian-origin influenza A (H7N9) virus.
Rongbao Gao (2013)
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
K. Liu (2011)
Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic
G. Smith (2009)
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.
D. Gupta (2013)
This paper is referenced by
QSAR study of N-substituted Oseltamivir derivatives as potent avian influenza virus H5N1 inhibitors using quantum chemical descriptors and statistical methods
Samir Chtita (2020)
Strategies for the Development of Influenza Drugs: Basis for New Efficient Combination Therapies
T. Steinmetzer (2014)
M. Stasevych (2019)
Synthesis of neuraminidase-resistant sialoside-modified three-way junction DNA and its binding ability to various influenza viruses.
Miyuki Yamabe (2019)
Discovery and SAR Research for Antivirus Activity of Novel Butenolide on Influenza A Virus H1N1 In Vitro and In Vivo
Zhen-ya Wang (2019)
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
H. Zhang (2020)
Tailor-Made Antimicrobial/Antiviral Star Polymer via ATRP of Cyclodextrin and Guanidine-Based Macromonomer
Yuanfeng Pan (2015)
Stereoselective Construction of Bridged trans-aza-Bicyclo[7/6,3/2,1]alkenyl Imines through Ring Expansion aza-Cope Rearrangement.
Mei-Hua Shen (2015)
Structure-activity relationships of 3-O-β-chacotriosyl ursolic acid derivatives as novel H5N1 entry inhibitors.
Gaopeng Song (2015)
The C=C Bond Decomposition Initiated by Enamine‐Azide Cycloaddition for Catalyst‐ and Additive‐Free Synthesis of N‐Sulfonyl Amidines
X. Zheng (2019)
A convenient one-pot synthesis of N-substituted amidoximes and their application toward 1,2,4-oxadiazol-5-ones
Wong Phakhodee (2018)
New small-molecule drug design strategies for fighting resistant influenza A
Z. Shen (2015)
Interception of amide ylides with sulfonamides: synthesis of (E)-N-sulfonyl amidines catalyzed by Zn(OTf)2.
J. Chen (2017)
Aminative umpolung synthesis of aryl vicinal diamines from aromatic aldehydes.
X. Liu (2014)
Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors
Martina Richter (2015)
Oseltamivir analogs with potent anti-influenza virus activity.
S. Kumar (2020)
Recent advances in the transformations of cycloalkane-fused oxiranes and aziridines
Melinda Nonn (2017)
A Novel Systematic Approach for Selection of Prodrugs Designed to Improve Oral Absorption.
Mai Shimizu (2020)
Substrate-dependent fluorinations of highly functionalized cycloalkanes
L. Kiss (2016)
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Y. Xie (2014)
Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae
U. Grienke (2016)
Using Bioisosteric Replacements to Enhance the Analgesic Properties of 4-Hydroxy-6,7-Dimethoxy-2-oxo-1,2-Dihydroquinoline-3-Carboxamides
I. Ukrainets (2016)
Design, Synthesis, and Evaluation of 3‐((4‐(t‐Butyl)‐2‐(2‐benzylidenehydrazinyl)thiazol‐5‐yl)methyl)quinolin‐2(1H)‐ones as Neuraminidase Inhibitors
Fang Yi-lin (2016)
Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
A. Hoffmann (2016)
Novel Furin Inhibitors with Potent Anti‐infectious Activity
Kornelia Hardes (2015)
Electrochemically generated N-iodoaminium species as key intermediates for selective methyl sulphonylimination of tertiary amines.
B. Huang (2020)
Synthetic Advancement of Neuraminidase Inhibitor “Tamiflu”
Bhagirath Limbani (2020)
Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases
A. Hoffmann (2017)
Structure-activity relationships of 3-O-β-chacotriosyl oleanic acid derivatives as entry inhibitors for highly pathogenic H5N1 influenza virus.
S. Li (2017)
Structure-activity relationships of 3-O-β-chacotriosyl oleanane-type triterpenoids as potential H5N1 entry inhibitors.
Gao-peng Song (2016)
The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors
X. Lin (2018)
Fluorination of some highly functionalized cycloalkanes: chemoselectivity and substrate dependence
A. Remete (2017)See more